Sanara Medtech Net Worth
Sanara Medtech Net Worth Breakdown | SMTI |
Sanara Medtech Net Worth Analysis
Sanara Medtech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sanara Medtech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sanara Medtech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sanara Medtech's net worth analysis. One common approach is to calculate Sanara Medtech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sanara Medtech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sanara Medtech's net worth. This approach calculates the present value of Sanara Medtech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sanara Medtech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sanara Medtech's net worth. This involves comparing Sanara Medtech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sanara Medtech's net worth relative to its peers.
Enterprise Value |
|
To determine if Sanara Medtech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sanara Medtech's net worth research are outlined below:
| The company reported the previous year's revenue of 64.99 M. Net Loss for the year was (4.3 M) with profit before overhead, payroll, taxes, and interest of 39.48 M. | |
| Sanara Medtech currently holds about 12.68 M in cash with (3.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.53. | |
| Sanara Medtech has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th |
Sanara Medtech Quarterly Good Will |
|
Sanara Medtech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sanara Medtech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sanara Medtech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Sanara Medtech Target Price Consensus
Sanara target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Sanara Medtech's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Sanara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Sanara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Sanara Medtech, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSanara Medtech Target Price Projection
Sanara Medtech's current and average target prices are 35.91 and 59.00, respectively. The current price of Sanara Medtech is the price at which Sanara Medtech is currently trading. On the other hand, Sanara Medtech's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Sanara Medtech Market Quote on 11th of December 2024
Target Price
Analyst Consensus On Sanara Medtech Target Price
Know Sanara Medtech's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sanara Medtech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sanara Medtech backward and forwards among themselves. Sanara Medtech's institutional investor refers to the entity that pools money to purchase Sanara Medtech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 13 K | Charles Schwab Investment Management Inc | 2024-09-30 | 11.4 K | Salem Investment Counselors Inc | 2024-09-30 | 11.2 K | Stephens Inc | 2024-09-30 | 10.8 K | Bank Of New York Mellon Corp | 2024-09-30 | 10.5 K | Lazard Asset Management Llc | 2024-09-30 | 7.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 7.4 K | State Board Of Admin Of Florida Retir | 2024-09-30 | 7.1 K | Barclays Plc | 2024-09-30 | 5.7 K | Blackrock Inc | 2024-06-30 | 197 K | Vanguard Group Inc | 2024-09-30 | 173 K |
Follow Sanara Medtech's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 320.1 M.Market Cap |
|
Project Sanara Medtech's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.07) | (0.07) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.10) | (0.10) |
When accessing Sanara Medtech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sanara Medtech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sanara Medtech's profitability and make more informed investment decisions.
Evaluate Sanara Medtech's management efficiency
Sanara Medtech has return on total asset (ROA) of (0.0508) % which means that it has lost $0.0508 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2028) %, meaning that it created substantial loss on money invested by shareholders. Sanara Medtech's management efficiency ratios could be used to measure how well Sanara Medtech manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.18. The current Return On Capital Employed is estimated to decrease to -0.07. As of now, Sanara Medtech's Total Current Assets are increasing as compared to previous years. The Sanara Medtech's current Intangible Assets is estimated to increase to about 47.2 M, while Non Currrent Assets Other are forecasted to increase to (18.1 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.39 | 5.65 | |
| Tangible Book Value Per Share | (0.48) | (0.50) | |
| Enterprise Value Over EBITDA | -1.2 K | -1.1 K | |
| Price Book Value Ratio | 7.59 | 7.97 | |
| Enterprise Value Multiple | -1.2 K | -1.1 K | |
| Price Fair Value | 7.59 | 7.97 | |
| Enterprise Value | 312.2 M | 176.8 M |
Understanding the operational decisions made by Sanara Medtech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 4.2296 | Revenue 78.1 M | Quarterly Revenue Growth 0.352 | Revenue Per Share 9.241 | Return On Equity (0.20) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sanara Medtech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sanara Medtech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sanara Medtech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sanara Medtech Corporate Filings
8K | 4th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 15th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Sanara Medtech Earnings Estimation Breakdown
The calculation of Sanara Medtech's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Sanara Medtech is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Sanara Medtech is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Sanara Medtech Earnings Projection Consensus
Suppose the current estimates of Sanara Medtech's value are higher than the current market price of the Sanara Medtech stock. In this case, investors may conclude that Sanara Medtech is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Sanara Medtech's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 34.35% | -0.34 | 0.0 | -0.99 |
Sanara Medtech Earnings per Share Projection vs Actual
Actual Earning per Share of Sanara Medtech refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Sanara Medtech predict the company's earnings will be in the future. The higher the earnings per share of Sanara Medtech, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Sanara Medtech Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Sanara Medtech, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Sanara Medtech should always be considered in relation to other companies to make a more educated investment decision.Sanara Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Sanara Medtech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.62 | -0.34 | 0.28 | 45 | ||
2024-08-12 | 2024-06-30 | -0.21 | -0.41 | -0.2 | 95 | ||
2024-05-13 | 2024-03-31 | -0.07 | -0.21 | -0.14 | 200 | ||
2024-03-25 | 2023-12-31 | -0.13 | -0.03 | 0.1 | 76 | ||
2023-11-13 | 2023-09-30 | -0.04 | -0.13 | -0.09 | 225 | ||
2023-08-14 | 2023-06-30 | -0.13 | -0.22 | -0.09 | 69 | ||
2023-05-15 | 2023-03-31 | -0.33 | -0.14 | 0.19 | 57 | ||
2023-03-20 | 2022-12-31 | -0.26 | -0.38 | -0.12 | 46 | ||
2022-11-14 | 2022-09-30 | -0.32 | -0.18 | 0.14 | 43 | ||
2022-08-15 | 2022-06-30 | -0.28 | -0.42 | -0.14 | 50 | ||
2022-03-31 | 2021-12-31 | -0.27 | -0.48 | -0.21 | 77 | ||
2021-11-12 | 2021-09-30 | -0.18 | -0.27 | -0.09 | 50 | ||
2021-08-16 | 2021-06-30 | -0.12 | -0.16 | -0.04 | 33 | ||
2011-11-14 | 2011-09-30 | -1 | -2.0 | -1.0 | 100 | ||
2011-08-22 | 2011-06-30 | -2 | -6.0 | -4.0 | 200 |
Sanara Medtech Corporate Management
| Bill Fitzgerald | Compliance Officer | Profile | |
| Jacob Waldrop | Chief Officer | Profile | |
| Callon Nichols | Director Relations | Profile | |
| Jane Fore | Chief Officer | Profile | |
| Tricia Matteson | Director Marketing | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanara Medtech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 9.241 | Quarterly Revenue Growth 0.352 | Return On Assets (0.05) | Return On Equity (0.20) |
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.